Q1 2025 Earnings Call Transcript May 6, 2025 Krystal Biotech, Inc. misses on earnings expectations. Reported EPS is $1.2 EPS, expectations were $1.38. Operator: Thank you for standing by, and welcome ...

Krystal Biotech KRYS reported first-quarter 2025 earnings per share (EPS) of $1.20, which missed the Zacks Consensus Estimate ...

VYJUVEK approved in Europe for the treatment of DEB patients from birth $88.2 million in 1Q VYJUVEK revenue and $429.4 million since launch in Q3 2023 Second ophthalmic program in clinic - KB801 for ...

Krystal Biotech, Inc.’s KRYS share price has dipped by 12.19%, which has investors questioning if this is right time to buy.

Krystal Biotech, Inc. announced that the European Commission has approved VYJUVEK® (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB ...

VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a ...

DEB is a rare and severe monogenic disease that affects the skin and mucosal tissues. It is caused by one or more mutations in a gene called COL7A1. As of April, Krystal secured more than 540 ...

Krishnan, Chairman and CEO of Krystal Biotech. “With today’s announcement of our second clinical-stage ophthalmology program, the near-term initiation of our registrational study in DEB ...

“Today’s approval is an exciting milestone for Krystal and the patients we aim to serve. After years of preparation in close coordination with leading DEB treatment centers, we are ready and ...

PITTSBURGH, May 06, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech ... Ophthalmology KB803 for the treatment of ocular complications of DEB The Company continues to enroll in its ongoing natural ...